HLA B-27

HLA-B27 positive means you carry a specific variant of a human leukocyte antigen involved in immune response. It raises the likelihood of certain inflammatory conditions—especially ankylosing spondylitis, reactive arthritis, uveitis, and some inflammatory arthritides—but is not diagnostic alone. Many carriers never develop disease; the result helps clinicians decide on further evaluation and monitoring.

HLA‑B27 is strongly associated with seronegative spondyloarthropathies, especially ankylosing spondylitis. It’s also linked to reactive arthritis, certain forms of psoriatic arthritis, and enteropathic arthritis associated with inflammatory bowel disease (Crohn’s, ulcerative colitis). HLA‑B27 increases risk of acute anterior uveitis and is seen in some enthesitis‑related juvenile idiopathic arthritis cases, and may contribute to axial inflammation.

HLA-B27 positivity alone is not life‑threatening. Most carriers never develop disease, but it increases risk for inflammatory conditions (e.g., ankylosing spondylitis, uveitis) that can cause chronic pain, functional problems, and rare complications if untreated. Early diagnosis and treatment lower risks. See a clinician if you have persistent back pain, stiffness, eye inflammation, or other concerning symptoms.

No — HLA‑B27 is not typically positive in rheumatoid arthritis. HLA‑B27 is mainly associated with seronegative spondyloarthropathies (like ankylosing spondylitis and reactive arthritis), whereas rheumatoid arthritis is more strongly linked to HLA‑DRB1 ("shared epitope") alleles. HLA‑B27 testing is not useful for diagnosing RA; diagnosis depends on clinical features, RF/anti‑CCP, and imaging.

HLA-B27 positivity itself isn’t treated—management targets any associated inflammatory disease (e.g., ankylosing spondylitis, reactive arthritis, uveitis). Treatment includes NSAIDs, exercise/physiotherapy, short corticosteroid courses or injections for flares, conventional DMARDs for peripheral arthritis, and biologics (TNF or IL‑17 inhibitors) for refractory axial disease. Treat infections when present and refer to a rheumatologist and ophthalmologist as needed.

HLA-B27 is a genetic marker linked to increased risk of inflammatory spinal conditions, especially ankylosing spondylitis, which cause chronic inflammatory back pain. The gene itself doesn’t directly cause pain; many carriers never develop disease. If you have persistent back pain with morning stiffness, night pain, or improvement with exercise, see a doctor—early diagnosis and treatment can limit progression and relieve symptoms.